deep vein thrombosis
Cardiovascular · 2012–2019
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| enoxaparin Prophylaxis or treatment of deep vein thrombosis (DVT) and venous thromboembolism (VTE) prophylaxis, with particular focus on extended VTE prophylaxis in… | Mar 2019 | Recommended with restriction | input received |
| nadroparin calcium Prophylaxis against DVT associated with general or orthopaedic surgery, treatment of DVT, and prevention of clotting during haemodialysis. | Jul 2015 | Recommended with restriction | none received |
| rivaroxaban Initial and continuing treatment of confirmed acute symptomatic deep vein thrombosis (DVT) without symptomatic pulmonary embolism (PE), and prevention of… | Mar 2012 | Recommended with restriction | no section in document |
| rivaroxaban Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation at risk of stroke (prior stroke/TIA/non-CNS systemic embolism or… | Mar 2012 | Recommended with restriction | unclear |
What the PBS pays
$160M in government benefit over 2024–25, across 3,121,520 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| rivaroxaban | $128M |
| enoxaparin | $32.5M |
Appraised elsewhere
NICE, in England and Wales, has appraised 2 technologies for this condition, recommending 2 . A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
| Technology | Appraisal | Outcome | Date |
|---|---|---|---|
| apixabanApixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism | TA341 | recommended | 2015-06 |
| rivaroxabanRivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism | TA261 | recommended | 2012-07 |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 2 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.